Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study
- 10 February 2013
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 31 (5), 565-572
- https://doi.org/10.1200/jco.2011.40.6272
Abstract
Purpose Randomized data suggest that single-fraction or short-course palliative radiation therapy (RT) is sufficient in the majority of patients with metastatic cancer. We investigated population-based patterns in the use of palliative RT among patients with metastatic non–small-cell lung cancer (NSCLC). Patients and Methods From patients diagnosed with lung cancer from 2003 to 2005 at a participating geographic or organizational site and who consented to the Cancer Care Outcomes Research and Surveillance Consortium study, we identified patients with metastatic NSCLC who had complete medical records abstractions. Patient characteristics and clinical factors associated with receipt of palliative RT and RT intensity (total dose and number of treatments) were evaluated with multivariable regression. Results Of 1,574 patients with metastatic NSCLC, 780 (50%) received at least one course of RT, and 21% and 12% received RT to the chest and bone, respectively. Use of palliative RT was associated with younger age at diagnosis and receipt of chemotherapy and surgery to metastatic sites. Among patients receiving palliative bone RT, only 6% received single-fraction treatment. Among patients receiving palliative chest RT, 42% received more than 20 fractions. Patients treated in integrated networks were more likely to receive lower doses and fewer fractions to the bone and chest. Conclusion When palliative RT is used in patients with metastatic NSCLC, a substantial proportion of patients receive a greater number of treatments and higher doses than supported by current evidence, suggesting an opportunity to improve care delivery.Keywords
This publication has 23 references indexed in Scilit:
- Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals Of Oncology, 2010
- Role of radiotherapy in the treatment of lymphomas of the gastrointestinal tractBest Practice & Research Clinical Gastroenterology, 2010
- Dissemination patterns in non-gastric MALT lymphomaHaematologica, 2008
- Assessment of Disease Dissemination in Gastric Compared With Extragastric Mucosa-Associated Lymphoid Tissue Lymphoma Using Extensive Staging: A Single-Center ExperienceJournal of Clinical Oncology, 2006
- Primary CNS Lymphoma of T-Cell Origin: A Descriptive Analysis From the International Primary CNS Lymphoma Collaborative GroupJournal of Clinical Oncology, 2005
- Clinical Presentation and Management of Marginal Zone LymphomasHematology-American Society Hematology Education Program, 2005
- Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissueBlood, 2003
- Outcome in Relation to Treatment Modalities in 48 Patients with Localized Gastric MALT Lymphoma: A Retrospective Study of Patients Treated During 1976-2001Leukemia & Lymphoma, 2003
- Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzedBlood, 2000
- Clinical Features, Treatment and Outcome in a Series of 93 Patients with Low-Grade Gastric MALT LymphomaLeukemia & Lymphoma, 1997